Reference Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type abstract
PMID
Authors Gordan Srkalovic; Michael Rothe; Pam K. Mangat; Elizabeth Garrett-Mayer; Kathryn F. Mileham; Bamidele Adesunloye; Natalia Colocci; M. Dwight Chen; Funda Meric-Bernstam; Evan Pisick; Alissa S. Marr; Amin Benyounes; Olatunji B. Alese; Abigail Gregory; Dominique C. Hinshaw; Gina N. Grantham; Susan Halabi; Richard L. Schilsky
Title Abstract CT226: Sunitinib (S) in patients (pts) with solid tumors with FGFR2 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Journal Vol Issue Date Pages Journal Short Title
Cancer Research 85 8_Supplement_2 April 15, 2025
URL https://aacrjournals.org/cancerres/article/85/8_Supplement_2/CT226/761479/Abstract-CT226-Sunitinib-S-in-patients-pts-with
Abstract Text Abstract Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohort of pts with solid tumors with FGFR2 alterations treated with S are reported. Methods: Eligible pts had solid tumors, measurable disease, ECOG performance status (PS) 0-2, adequate organ function, and no standard treatment (tx) options. Genomic testing was performed in CLIA-certified, CAP-accredited site selected labs. Pts received S at 50 mg orally once daily for 4 weeks (wks) followed by 2 wks off, until disease progression. Low accruing histology-specific cohorts with FGFR2 alteration were collapsed into 1 histology-pooled cohort for analysis. Primary endpoint was disease control (DC) per investigator defined as complete or partial response (PR) or stable disease (SD) of 16+ wks duration (SD16+) per RECIST v1.1. The hypothesized null DC rate of 15% was evaluated by a 1-sided exact binomial test (alpha 0.10; 82% power). Secondary endpoints were progression-free survival (PFS), overall survival (OS), objective response (OR), duration of response (DOR) and SD, and safety. Results: 28 pts with ten different solid tumors with FGFR2 mutation (mut) (n=19), FGFR2 amplification (amp) (n=2), FGFR2 amp and mut (n=4), FGFR2 fusion (n=2), or FGFR2 fusion, mut, and amp (n=1) were enrolled. Table shows demographics, outcomes, and toxicity. 3 PR (lung [2], uterus [1]; FGFR2 mut [3]) and 8 SD16+ (lung [2], ovary [2], cholangiocarcinoma [1], gallbladder [1], osteosarcoma [1], uterus [1]; FGFR2 mut [6], fusion [1], or amp and mut [1]) were observed for a DC rate of 39% (1-sided 90% CI, 27 to 100) and an OR rate of 11% (95% CI, 2 to 28). The null DC rate was rejected (p=0.0015). 10 pts had ≥1 grade 3 tx-related adverse (AE) or serious AE. Conclusions: S met prespecified criteria to declare a signal of activity in pts with solid tumors with FGFR2 alterations.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 mutant Advanced Solid Tumor predicted - sensitive Sunitinib Phase II Actionable In a Phase II trial (TAPUR), Sutent (sunitinib) treatment resulted in a disease control rate of 39% (11/28) and an objective response rate of 11% (3/28, all partial responses (PR)) in advanced solid tumor patients harboring FGFR2 alterations including mutation (n=19), amplification (amp) (n=2), fusion (n=2), mutation and amp (n=4), or fusion, mutation, and amp (n=1), with 2 PR in lung cancer and 1 PR in uterine cancer harboring FGFR2 mutations (Cancer Res (2025) 85 (8_Supplement_2): CT226). detail...